PTGER3 and cervical cancer: Our latest publication observed that enhanced expression of EP3 (IRS ≥ 2) is correlated with a poor prognosis in the OS of 250 cervical cancer patients after a 20-year follow-up analysis (Heidegger et al. 2017).